MST01-AZN-05
Brief description of study
To assess the localized PD in the TME following intratumoral administration of subtherapeutic microdoses of anti-cancer therapies, and to assess the safety of subtherapeutic microdoses of anti-cancer therapies when administered intratumorally via the CIVO device. Localized intratumoral PD biomarkers will be assessed by spatial profiling (NanoString GeoMx Digital Spatial Profiler) in resected tissues encompassing the region injected by the CIVO device. PD biomarker analysis will assess molecular signature of TME response to drug, tumor cell viability, tumor and immune cell spatial relationships, and other biomarkers.
Additional analyses including, but not limited to, multiplexed immunohistochemistry (IHC) and RNA-based readouts of tumor responses to drug microdose injection may be performed on the research sample. The safety and tolerability of intratumoral microdosing with anti-cancer therapies will be assessed by monitoring of adverse events.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
TBD
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
